How Tumor Stiffness May Rewire RNA Chemistry to Help Cancers Evade Immunity

Solid tumors are not just collections of rogue cells dividing out of control; they are physically abnormal ecosystems. Extracellular matrix stiffening, compressive stress, elevated interstitial fluid pressure, and aberrant fluid flow all conspire to reshape how cancer cells, stromal cells, and immune cells behave within the tumor mass. At the same time, a separate line of research has revealed that the chemical decoration of RNA molecules, known collectively as the epitranscriptome, acts as a dynamic regulatory layer controlling RNA stability, translation, splicing, localization, and even immune recognition. A new review published in Molecular Cancer argues that these two fields, traditionally studied in isolation, are deeply intertwined. The authors, led by Mingyang Jiang and colleagues at Guangxi Medical University and collaborating institutions across China, Spain, and the United Kingdom, propose a unifying framework they call mechanosensitive epitranscriptomics, in which the mechanical forces inside tumors directly influence RNA modification patterns, and those patterns in turn shape how cancers evade the immune system.

The review begins by cataloguing the mechanical abnormalities that define the solid tumor microenvironment. Desmoplastic tumors, such as pancreatic ductal adenocarcinoma, deposit dense stromal matrix rich in collagen, crosslinked in part by enzymes like lysyl oxidase, producing tissue that can be far stiffer than healthy surrounding tissue. Growing cell masses generate solid stress that compresses blood and lymphatic vessels, raising interstitial fluid pressure and distorting fluid flow. Cancer-associated fibroblasts amplify this stiffness by contracting the matrix and depositing new extracellular material. These physical cues are not passive background conditions; cells sense them through integrin-based adhesions, mechanosensitive ion channels, and cytoskeletal networks, converting mechanical information into biochemical signals that reach all the way into the nucleus and alter gene expression.

The canonical mechanotransduction pathways described in the review provide plausible routes by which physical forces could reach the RNA modification machinery. Integrin-focal adhesion kinase signaling couples matrix rigidity to downstream cascades including PI3K-AKT, MAPK, and Rho-associated kinase pathways. The transcriptional coactivators YAP and TAZ, which respond to substrate stiffness and cytoskeletal tension, shuttle into the nucleus under mechanical loading and reprogram transcription. The stretch-activated ion channel PIEZO1 converts membrane tension into calcium influx, triggering downstream signaling. Cytoskeletal remodeling and nuclear deformation, mediated in part by LINC complexes that physically connect the cytoskeleton to the nuclear interior, can even alter chromatin organization directly. Each of these conduits, the authors argue, represents a potential input channel to the enzymes that write, erase, and read chemical marks on RNA.

Those enzymes are the heart of the epitranscriptome. N6-methyladenosine, or m6A, is the most abundant internal modification of messenger RNA and is installed by writer complexes containing METTL3, METTL14, and WTAP, removed by erasers such as FTO and ALKBH5, and interpreted by readers including YTHDF proteins and IGF2BP family members. Other modifications, including 5-methylcytosine, 7-methylguanosine, and pseudouridine, together with adenosine-to-inosine RNA editing, further diversify the informational content of the transcriptome. The review emphasizes that the activity, localization, and expression of these writers, erasers, and readers could plausibly be modulated by mechanical signaling. For example, YAP/TAZ-driven transcriptional programs could alter the expression levels of modification enzymes, while calcium influx through PIEZO1 could regulate enzymatic activity through calcium-dependent signaling, and nuclear deformation could influence where modification enzymes reside within the cell.

The most striking aspect of the review is its intellectual honesty about the state of the evidence. The authors applied a tiered classification to the studies they surveyed and found that only two investigations meet the strictest Tier-1 definition of mechanosensitive epitranscriptomics in cancer-relevant systems. The first is a study in pancreatic ductal adenocarcinoma showing that substrate stiffness influences the METTL14 and IGF2BP3 axis in a YAP1-dependent manner, linking matrix rigidity to m6A deposition and downstream oncogenic outputs. The second demonstrates that mechanical stiffness regulates the m6A eraser FTO in macrophages, thereby controlling Socs1 expression and shaping macrophage polarization, a process central to tumor immune dynamics. Most other reported connections between mechanics and RNA modification, the authors caution, remain Tier-3 hypotheses or associations potentially confounded by parallel changes in oxygen tension, inflammation, or metabolism that accompany altered mechanical environments.

Distinguishing direct mechanoregulation from these secondary effects is a central challenge the review confronts head-on. A stiff, hypoperfused tumor region is simultaneously stiff, hypoxic, nutrient-deprived, and inflamed. Hypoxia-inducible factors can independently regulate RNA modification enzymes, and inflammatory cytokines such as transforming growth factor beta do the same. To untangle this web, the authors propose testable experimental models: decoupling stiffness from hypoxia using engineered matrices, applying controlled mechanical stretch to cells in isolation, and using temporally precise perturbations to determine whether mechanical inputs causally drive changes in RNA modification rather than merely correlating with them. Such designs, they argue, are essential before the field can claim that mechanics acts directly on the epitranscriptomic machinery rather than through intermediary stress responses.

The tumor-immune interface is where the stakes of this framework become highest. Mechanical stress and RNA modifications jointly influence nearly every process that determines whether a tumor is recognized and destroyed by the immune system. Antigen presentation depends on the translation and processing of major histocompatibility complex components, processes that m6A and other modifications can tune. Interferon signaling, which alert neighboring cells to the presence of tumor antigens, is sensitive to RNA editing levels, since adenosine-to-inosine editing can alter how double-stranded RNA is perceived by innate immune sensors. Checkpoint molecules such as PD-L1 are themselves subject to RNA modification control. The review details how these regulatory layers could affect T-cell and natural killer cell function, the polarization of myeloid cells toward immunosuppressive fates, and the physical exclusion of immune cells from tumor nests, where stromal stiffness forms a mechanical barrier to immune infiltration.

On the translational side, the review outlines strategies for converting this framework into clinical tools. Magnetic resonance elastography already allows noninvasive mapping of tissue stiffness in patients, and combining such mechanical imaging with single-cell epitranscriptomic profiling, using methods like single-cell RNA sequencing, methylated RNA immunoprecipitation sequencing, and deamination-based modification mapping, could reveal how mechanical niches within tumors correspond to distinct RNA modification states. The authors envision composite biomarkers that integrate tumor mechanics, epitranscriptomic signatures, and predicted immunotherapy response, potentially identifying patients likely to benefit from immune checkpoint blockade. They also suggest that enzymes such as FTO, METTL14, or METTL3 could themselves become therapeutic targets, either alone or in combination with mechanical normalization strategies such as drugs that reduce matrix stiffness or stromal pressure, thereby softening the tumor microenvironment while simultaneously reprogramming RNA regulation.

What makes this review compelling is its refusal to overstate a young field. By explicitly ranking the evidence and naming the two Tier-1 studies, the authors provide a benchmark against which future work can be measured, and they openly acknowledge that much of the mechanosensitive epitranscriptomic landscape in cancer remains hypothetical. Yet the framework they assemble is rich with testable predictions: that specific mechanotransduction channels converge on specific modification enzymes, that these enzymes modify specific transcript subsets governing immune recognition, and that disrupting these circuits could restore immune visibility to mechanically armored tumors. As sequencing technologies for RNA modifications grow faster and more precise, and as engineered matrices allow cleaner mechanical experiments, the coming years should reveal whether the convergence of tumor mechanics and RNA chemistry is a genuine biological axis or a seductive correlation. Either way, the review establishes a clear roadmap for finding out, and in doing so adds a provocative new dimension to the ongoing effort to understand why some tumors so successfully hide from the immune system.

Subject of Research: How tumor mechanics regulate RNA modifications and immune escape in cancer

Article Title: Mechanosensitive epitranscriptomics in cancer: linking tumor mechanics, RNA modification, and immune escape

Article References: Jiang, M., Zhang, K., Li, M., Yao, J., Shi, R., Sun, C., Rodríguez, R. A., Lin, Z., Meng, J., Wang, Z., Wu, S., Luo, M., Zhang, W., Wei, R., Bai, Y., Lai, G., Zhang, C., Bo, Z., & Wang, T. (2026). Mechanosensitive epitranscriptomics in cancer: linking tumor mechanics, RNA modification, and immune escape. Molecular Cancer. https://doi.org/10.1186/s12943-026-02784-6

Image Credits: AI Generated

DOI: 10.1186/s12943-026-02784-6

Keywords: mechanosensitive epitranscriptomics, RNA modifications, m6A, mechanotransduction, tumor microenvironment, immune escape, cancer immunotherapy, YAP/TAZ, METTL14, FTO, tumor stiffness, Molecular Cancer